et al., Journal of the Association of Physicians India, 69:11 (Peer Reviewed)
Physician survey in India with 164 ivermectin prophylaxis, 129 HCQ prophylaxis, and 81 control patients, showing significantly lower COVID-19 cases with treatment. Details of the treatment and control groups and the definition of cases are not provided, and the results are subject to survey bias. Authors also report on community prophylaxis but present only combined ivermectin/HCQ results.
risk of case, 74.5% lower, RR 0.25, p < 0.001, treatment 12 of 129 (9.3%), control 29 of 81 (35.8%), odds ratio converted to relative risk, physician survey.
risk of case, 48.6% lower, RR 0.51, p = 0.03, treatment 11 of 109 (10.1%), control 39 of 200 (19.5%), odds ratio converted to relative risk, combined ivermectin or HCQ in community.
This study is excluded in the after exclusion results of meta
minimal details provided, unadjusted results with no group details, results may be significantly affected by survey bias.
Samajdar et al., 11/17/2021, retrospective, India, South Asia, peer-reviewed, 9 authors, dosage not specified.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.